György Végh
Semmelweis University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by György Végh.
European Journal of Obstetrics & Gynecology and Reproductive Biology | 2004
József Bátorfi; György Végh; János Szepesi; Ivan Szigetvari; József Doszpod; Vilmos Fülöp
Abstract Objective : We analyzed human chorionic gonadotropin (hCG) follow-up data of patients with molar pregnancy. Women often do not complete recommended post-disease screening. Our purpose was to determine if continuing follow up of uncomplicated molar cases beyond attaining undetectable hCG levels is necessary for detecting relapse of gestational trophoblastic disease. Study design : One hundred fifty patients treated at Hungarian National Health Center were analyzed. Those who developed persistent disease before hCG had become undetectable were excluded from further analysis ( n =24; 16%). Results : Among 126 uncomplicated cases, 72 patients (57%) completed follow up, and 54 (43%) discontinued their protocol before it had been completed. Of 120 patients who achieved at least one undetectable hCG level, none had any evidence of relapse. Conclusion : In uncomplicated hydatidiform mole, our analysis indicates that once undetectable serum hCG levels are attained, relapse is unlikely. Although further monthly checks are advisable, the likelihood of recurrence appears very low.
Obstetrical & Gynecological Survey | 2004
József Bátorfi; György Végh; János Szepesi; Ivan Szigetvari; József Doszpod; Vilmos Fülöp
OBJECTIVE We analyzed human chorionic gonadotropin (hCG) follow-up data of patients with molar pregnancy. Women often do not complete recommended post-disease screening. Our purpose was to determine if continuing follow up of uncomplicated molar cases beyond attaining undetectable hCG levels is necessary for detecting relapse of gestational trophoblastic disease. STUDY DESIGN One hundred fifty patients treated at Hungarian National Health Center were analyzed. Those who developed persistent disease before hCG had become undetectable were excluded from further analysis (n=24; 16%). RESULTS Among 126 uncomplicated cases, 72 patients (57%) completed follow up, and 54 (43%) discontinued their protocol before it had been completed. Of 120 patients who achieved at least one undetectable hCG level, none had any evidence of relapse. CONCLUSION In uncomplicated hydatidiform mole, our analysis indicates that once undetectable serum hCG levels are attained, relapse is unlikely. Although further monthly checks are advisable, the likelihood of recurrence appears very low.
Gynecologic Oncology | 2000
Z. Selcuk Tuncer; György Végh; Vilmos Fülöp; David R. Genest; Samuel C. Mok; Ross S. Berkowitz
Gynecologic Oncology | 1999
György Végh; Z. Selcuk Tuncer; Vilmos Fülöp; David R. Genest; Samuel C. Mok; Ross S. Berkowitz
Gynecologic Oncology | 1999
György Végh; Vilmos Fülöp; Yan Liu; Shu Wing Ng; Z. Selcuk Tuncer; David R. Genest; Piroska Páldi-Haris; János Földi; Samuel C. Mok; Ross S. Berkowitz
Journal of Reproductive Medicine | 2008
György Végh; Ivan Szigetvari; Ibolya Soltész; Katalin Major; József Bátorfi; János Dancsó; László Zsirai; Vilmos Fülöp
Journal of Reproductive Medicine | 2010
Vilmos Fülöp; Ivan Szigetvari; János Szepesi; György Végh; József Bátorfi; Zoltan Nagymanyoki; Miklós Török; Ross S. Berkowitz
Journal of Reproductive Medicine | 2012
Vilmos Fülöp; Ivan Szigetvari; János Szepesi; György Végh; Margit Singh; Ross S. Berkowitz
Orvosi Hetilap | 2001
Vilmos Fülöp; György Végh; József Doszpod
Journal of Reproductive Medicine | 2016
Vilmos Fülöp; Ivan Szigetvari; János Szepesi; György Végh; László Zsirai; Ross S. Berkowitz